Epizyme Announces Conference Call to Discuss Phase 2 Tazemetostat Follicular Lymphoma Data

67

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Epizyme, Inc. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call on Friday, June 21, 2019 at 8:30 a.m. ET to discuss updated data from an ongoing Phase 2 study of its lead candidate, tazemetostat, as a monotherapy for patients with relapsed or refractory follicular lymphoma. The data, which will be from a recent June 2019 data cutoff date, will be reported in

 

http://www.businesswire.com/news/home/20190612005047/en/Epizyme-Announces-Conference-Call-Discuss-Phase-2/